{'fraction_non_alphanumeric': 0.02416918429003021, 'fraction_numerical': 0.03121852970795569, 'mean_word_length': 4.9879518072289155, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Single intramuscular injection of aztreonam in the treatment of uncomplicated gonorrhoea in women.

A total of 225 female patients with uncomplicated gonorrhoea was treated at random with either a single intramuscular injection of 1 g aztreonam or with 2.4 mega units procaine penicillin intramuscularly plus 1 g probenacid orally. Patients were followed up at 1, 2 and 3 weeks for bacteriological tests. The success rate among 101 of 116 patients on aztreonam who attended at least 1 follow-up examination after treatment was 100%, including 11 cases with penicillinase-producing N. gonorrhoeae. The minimum inhibiting concentrations of aztreonam in vitro were very much lower than the serum concentration, all strains being sensitive at 0.5 micrograms/ml or less. In a comparative group of 109 women treated with penicillin, there were 11 failures (penicillinase-producing N. gonorrhoeae strains) in 98 women who were followed-up. Aztreonam was well tolerated and there were no side-effects.